Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for Eisai’s in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima? / Kisplyx?, “lenvatinib”) for use in the treatment of hepatocellular carcinoma (HCC) in China.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that the results of a subpopulation analysis of patients from the Greater Chinese Region (mainland China, HKSA, and Chinese Taiwan) in a Phase III trial (REFLECT / Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima? / Kisplyx?, “lenvatinib”) versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma (HCC) were orally presented for the first time during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), which took place in Xiamen (Amoy) in the Fujian Province of China. Over half of the world‘s HCC patients come from the Greater Chinese Region.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that the results of a subpopulation analysis of patients with hepatitis B virus (HBV) coinfection in a Phase III trial (REFLECT / Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima? / Kisplyx?, “lenvatinib”) versus sorafenib as a first-line treatment for unresectable HCC were presented for the first time during the 11th Annual Conference of the International Liver Cancer Association (ILCA) held in Seoul, South Korea.?
On September 15, 2017, China Population Welfare Foundation, Alzheimer’s Disease Chinese (ADC) and Eisai China Inc. (ECI) jointly kicked off the “Yellow Bracelet” activity for caring the patients with Alzheimer‘s disease. In line with the corporate philosophy of “human health care?(hhc)” and according to the actual situation of Chinese patients, Eisai introduced into China the experiences for the treatment and care of the aging people of Japan in hope of continuously enhancing the attention of the whole?Chinese society?to the Alzheimer’s Disease and improving the grim situation of China‘s insufficient treatments and care concerning this disease through upgrading the entire solution that covering recognition, trainings and care. Chairman Hao Linna of China Population Welfare Foundation, professor Wang Luning from Alzheimer’s Disease Chinese, Professor Xie Hengge from the General Hospital of People‘s Liberation Army of China, Professor Wang Huali from Peking University Sixth Hospital (Institute of Mental Health), Professor Liu Xueyuan from the Tenth People’s Hospital Affricated to Tongji University, Professor He Jincai from the First Affiliated Hospital of Wenzhou Medical College, Mr. Kaneko Norio, the president of ECI and Ms. Feng Yanhui, the General Manager of ECI attended the conference and delivered speeches. The guests jointly kicked off the “Alzheimer‘s Care” activity and witnessed the important moment.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for a fifth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).
Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, CEO: Haruo Naito, “Eisai”) and Ono Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, Representative Director and President: Gyo Sagara, “Ono”) have announced that they have entered into a collaboration agreement to jointly develop the combination therapy of Eisai‘s multi-kinase inhibitor, Lenvima? (lenvatinib mesylate) and Ono’s human anti-human PD-1 (programmed cell death-1) monoclonal antibody, Opdivo? (nivolumab) for the treatment of hepatocellular carcinoma (HCC).
Following the 101st?place in 2014 and the 97th?place in 2015, Eisai China Inc., harvested the 92nd?place in the 2016 China Top 100 Pharmaceutical Enterprises List announced by China National Pharmaceutical Industry Information Center. Mr. Zhang Jiekui, Senior Director of Policy Administration of Eisai China Inc., accepted the award on behalf of the company.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that on July 26, 2017 (U.S. time), its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for Eisai’s antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). This follows the application in Japan. Lenvatinib for the treatment of HCC is designated as an orphan drug by the FDA.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima? / Kisplyx?, “lenvatinib”) against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States. In this study, lenvatinib was the first agent to demonstrate statistical non-inferiority against sorafenib in the primary endpoint of Overall Survival (OS) and showed statistically significant and clinically meaningful improvements in the secondary endpoints of Progression Free Survival (PFS), Time To Progression (TTP), and Objective Response Rate (ORR), doubling sorafenib‘s median values and ratios.
